HIV-1 Genotyping and Tropism Assay via Single-Genome Sequencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting HIV drug resistance and coreceptor tropism are limited by their inability to accurately identify low-frequency variants, particularly those present in less than 20% of the viral population, leading to incomplete treatment strategies and potential drug resistance issues.
Innovation Solution
A deep sequencing method that amplifies and sequences HIV genomic regions encoding Gag proteins and the env-C2V3 region from patient samples, allowing for the detection of variants at frequencies as low as 1% through next-generation sequencing techniques, enabling precise identification of drug-resistant and tropism-associated variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If population sequencing methods are used for HIV genotyping, then the assay is simpler and faster, but the ability to detect low-frequency variants below 20% is insufficient
Solution Approach 1:
The patent divides the HIV viral population into individually sequenced genomic segments through single-genome amplification and cloning. Each cloned genome is sequenced separately, allowing detection of minority variants at frequencies as low as 1% by examining individual viral genomes rather than averaging across populations.
Solution Approach 2:
The patent transitions from population-level sequencing to single-genome sequencing, adding the dimension of individual genome resolution. This enables detection of rare variants by examining each viral genome independently rather than relying on bulk population signals that mask low-frequency variants.
2Measurement precision
If phenotypic assays are used to determine HIV coreceptor tropism, then accuracy is improved, but turnaround time increases and cost increases
Solution Approach 1:
The patent performs genotypic analysis of the V3 region with high sensitivity to predict coreceptor tropism before clinical decisions are made. By using deep sequencing to accurately determine viral genotype, the assay provides predictive information that guides tropism-based treatment decisions without requiring time-consuming phenotypic confirmation.
Solution Approach 2:
The patent replaces complex phenotypic assays (cell-based functional tests) with a streamlined genotypic sequencing approach. By substituting the mechanical and biological complexity of phenotypic tropism assays with targeted genetic sequencing and bioinformatic prediction, the method achieves comparable accuracy with significantly reduced turnaround time and cost.
3Productivity
If genotypic assays are used for HIV drug resistance testing, then cost is reduced and speed is improved, but sensitivity to detect minority resistant variants below 20% is insufficient
Solution Approach 1:
The patent segments the viral population into individual genomes through single-genome amplification and cloning. Each cloned genome is independently sequenced, enabling detection of drug-resistant minority variants at frequencies as low as 1% while maintaining the efficiency and cost-effectiveness of genotypic testing methods.
Data Source
AI summary
A method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance and HIV tropism includes generating a plurality of cDNA species from a plurality of RNA molecules in an HIV sample population, amplifying a plurality of first amplicons and second amplicons from the cDNA species, wherein the first amplicons are amplified using first pairs of primers that amplify a HIV genomic region of the cDNA species encoding the Gag proteins p2, p7, p1 and p6, and the protease, reverse transcriptase, and integrase enzymes and the second amplicons are amplified using second pairs of primers that amplify a HIV genomic encoding region of the cDNA species encoding the env-C2V3 region; determining the nucleic acid sequence compositions of the amplified first amplicons second amplicons; identifying variants in the determined sequence by comparing the determined nucleic sequence to a guide sequence; and correlating the determined variants with variants of HIV drug resistance and HIV tropism.